% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Jung:131758,
      author       = {S. Jung and N. Allen and A. A. Arslan and L. Baglietto and
                      A. Barricarte and L. A. Brinton and B. L. Egleston and R. T.
                      Falk and R. T. Fortner$^*$ and K. J. Helzlsouer and Y. Gao
                      and A. Idahl and R. Kaaks$^*$ and V. Krogh and M. A. Merritt
                      and E. Lundin and N. C. Onland-Moret and S. Rinaldi and H.
                      Schock$^*$ and X.-O. Shu and P. M. Sluss and P. N. Staats
                      and C. Sacerdote and R. C. Travis and A. Tjønneland and A.
                      Trichopoulou and S. S. Tworoger and K. Visvanathan and E.
                      Weiderpass and A. Zeleniuch-Jacquotte and J. F. Dorgan},
      title        = {{A}nti-{M}üllerian hormone and risk of ovarian cancer in
                      nine cohorts.},
      journal      = {International journal of cancer},
      volume       = {142},
      number       = {2},
      issn         = {0020-7136},
      address      = {Bognor Regis},
      publisher    = {Wiley-Liss},
      reportid     = {DKFZ-2018-00057},
      pages        = {262 - 270},
      year         = {2018},
      abstract     = {Animal and experimental data suggest that anti-Müllerian
                      hormone (AMH) serves as a marker of ovarian reserve and
                      inhibits the growth of ovarian tumors. However, few
                      epidemiologic studies have examined the association between
                      AMH and ovarian cancer risk. We conducted a nested
                      case-control study of 302 ovarian cancer cases and 336
                      matched controls from nine cohorts. Prediagnostic blood
                      samples of premenopausal women were assayed for AMH using a
                      picoAMH enzyme-linked immunosorbent assay. Odds ratios (ORs)
                      and $95\%$ confidence intervals (CIs) were calculated using
                      multivariable-adjusted conditional logistic regression. AMH
                      concentration was not associated with overall ovarian cancer
                      risk. The multivariable-adjusted OR $(95\%$ CI), comparing
                      the highest to the lowest quartile of AMH, was 0.99
                      (0.59-1.67) (Ptrend : 0.91). The association did not differ
                      by age at blood draw or oral contraceptive use (all
                      Pheterogeneity : ≥0.26). There also was no evidence for
                      heterogeneity of risk for tumors defined by histologic
                      developmental pathway, stage, and grade, and by age at
                      diagnosis and time between blood draw and diagnosis (all
                      Pheterogeneity : ≥0.39). In conclusion, this analysis of
                      mostly late premenopausal women from nine cohorts does not
                      support the hypothesized inverse association between
                      prediagnostic circulating levels of AMH and risk of ovarian
                      cancer.},
      keywords     = {Biomarkers (NLM Chemicals) / Anti-Mullerian Hormone (NLM
                      Chemicals)},
      cin          = {C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28921520},
      pmc          = {pmc:PMC5749630},
      doi          = {10.1002/ijc.31058},
      url          = {https://inrepo02.dkfz.de/record/131758},
}